biologics - International Pharmaceutical Industry

Current Features

Transforming the Biologics Product Lifecycle with Inhalation Innovation

In recent years, the biopharmaceuticals landscape has witnessed a revolutionary shift with the emergence of new nasal inhalation technologies. Among these, soft mist...

15 April 2024 Current Features | Volume 16 Issue 1 biologics | delivery

Continue Reading →

Volume 15 Issue 4

Mastering the Immune Response: Immunogenicity Management in Biologics

The advent of therapeutic proteins and gene therapies has been a beacon of hope for treating complex diseases. Yet, these innovative treatments often face the signif...

19 December 2023 Volume 15 Issue 4 biologics | development

Continue Reading →

Volume 15 Issue 2

How to Harness the Benefits of Inhalation When Re-formulating Biologics

The biologics market is growing rapidly and is on track to be worth $719.14 bn by 2030, up from $366.6 bn in 2021.¹ This growth is being driven primarily by the risi...

3 July 2023 Volume 15 Issue 2 Benefits | biologics

Continue Reading →

Volume 15 Issue 2

Cutting-edge Formulation is Needed to Enable the Next Generation of Oral Biologics

An Introduction to Oral Solid Dose Traditionally, the pharmaceutical market has been dominated by oral drug delivery – whether oral solid dose (OSD) or liquid suspen...

3 July 2023 Volume 15 Issue 2 biologics | cutting-edge

Continue Reading →

News

New sterile Fill and Finish area for vials and prefilled syringes at Aenova

The new sterile area at the Aenova site in Latina, Italy, goes into commercial production end of October 2021. This first phase of an around 16 million euros inv...

20 October 2021 News Aenova | biologics

Continue Reading →

News

Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement

Updates 2018 Full Year and Second Quarter Financial Guidance Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has received $47 million as a result of ...

3 July 2018 News $47M | biologics

Continue Reading →

News

Oxford Genetics announces adeno-associated virus collaboration with MeiraGTx

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has established a new agreement ...

5 December 2017 News AAV vector | adeno-associated

Continue Reading →

News

Vetter expands its footprint in Asia Pacific region

Vetter, one of the global leaders in prefilled drug-delivery systems, today announced the official opening of a new branch office in South Korea. The new office in S...

9 November 2017 News biologics | biopharmaceutical

Continue Reading →

AeroGo

Integrated Product Development by PharmaLex

It’s All About Stem Cells

Covid 19

Current Edition

Transforming the Biologics Product Lifecycle with Inhalation Innovation

Mastering the Immune Response: Immunogenicity Management in Biologics

How to Harness the Benefits of Inhalation When Re-formulating Biologics

Cutting-edge Formulation is Needed to Enable the Next Generation of Oral Biologics

New sterile Fill and Finish area for vials and prefilled syringes at Aenova

Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement

Oxford Genetics announces adeno-associated virus collaboration with MeiraGTx

Vetter expands its footprint in Asia Pacific region

International Pharmaceutical Industry